The forecast for antidepressant medicine sales in Canada shows a steady increase from $1.38 billion in 2024 to $1.49 billion in 2028. In comparison to 2023, the sales stood at $1.34 billion. The year-on-year growth from 2023 to 2024 is approximately 2.99%, from 2024 to 2025 is about 2.90%, from 2025 to 2026 is approximately 1.41%, from 2026 to 2027 is around 2.08%, and from 2027 to 2028 is about 1.36%. The compound annual growth rate (CAGR) over the five-year forecast period (2024-2028) is approximately 2.15%.
Future trends to watch for include developments in new antidepressant therapies, advances in personalized medicine, and an increasing focus on mental health awareness and treatment accessibility, which could further influence the market dynamics.
